479 related articles for article (PubMed ID: 25584719)
1. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
4. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
[TBL] [Abstract][Full Text] [Related]
5. [
Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125
[TBL] [Abstract][Full Text] [Related]
6. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
7. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
8. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
11. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
12. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
13. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutations in thyroid cancer.
Liu R; Xing M
Endocr Relat Cancer; 2016 Mar; 23(3):R143-55. PubMed ID: 26733501
[TBL] [Abstract][Full Text] [Related]
16. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer.
Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897
[TBL] [Abstract][Full Text] [Related]
17. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
18. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
19. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
20. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Landa I; Ganly I; Chan TA; Mitsutake N; Matsuse M; Ibrahimpasic T; Ghossein RA; Fagin JA
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1562-6. PubMed ID: 23833040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
